Natera Exec Sells $596K in Stock Under Pre-Arranged 10b5-1 Plan
Natera, Inc.
Subscribe to track NTRA
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Natera Exec Sells $596K in Stock Under Pre-Arranged 10b5-1 Plan
Company: Natera, Inc. (NTRA) Form: 4 | Filed: 2025-11-04 Significance: Low
Insider: Moshkevich Solomon Title: PRESIDENT, CLINICALDIAGNOSTICS | Relationship: Officer
Transaction: • Type: Sell • Shares: 3,000 • Price: ~$198.60 (avg) • Value: $595,810 • Owned After: 112,061
Key Insight: A President at Natera sold a small portion (~2.6%) of their holdings under a pre-scheduled 10b5-1 trading plan, indicating the sale was likely for personal financial management rather than a reflection of company outlook.
Market Context: The transaction is minor, representing just 0.002% of Natera's $27.21B market cap. Such planned sales by executives are routine and typically have no market impact.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Natera, Inc. (NTRA)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A company President conducted a small, pre-planned sale of common stock, representing a negligible fraction of the company's market capitalization and the insider's total holdings.
- Market Impact: Neutral. The transaction was executed under a Rule 10b5-1 plan, which strips it of most informational value regarding the company's future prospects.
Company Information
| Field | Value |
|---|---|
| Company | Natera, Inc. |
| Ticker Symbol | NTRA |
| CIK | 0001604821 |
| Industry | SERVICES-MEDICAL LABORATORIES |
Insider Information
| Field | Value |
|---|---|
| Name | Moshkevich Solomon |
| CIK | 0002010019 |
| Title/Position | PRESIDENT, CLINICALDIAGNOSTICS |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-03 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 3,000 |
| Average Price Per Share | $198.60 |
| Total Value | $595,810 |
| Shares Owned After | 112,061 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $595,810.04 |
| % of Market Cap | 0.002% |
| Shares Transacted | 3,000 |
| % of Shares Outstanding | 0.002% |
| Post-Transaction Ownership | 112,061 shares (0.082% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The ~$596k sale is insignificant relative to Natera's $27.21 billion market capitalization.
- Ownership Concentration: The insider's post-transaction ownership of 0.082% is not a controlling stake. The sale of 3,000 shares represents only about 2.6% of the insider's prior holdings, indicating it was not a major liquidation event.
- Transaction Significance: The transaction is considered routine and not significant due to its small size relative to both market cap and shares outstanding.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sale was conducted under a pre-arranged 10b5-1 plan, indicating it was for personal liquidity or diversification, not a reaction to non-public information. The size is too small to influence the market.
Volume & Sentiment
- Expected Volume Impact: Negligible. The transaction size is a tiny fraction of typical daily trading volume for a multi-billion dollar company.
- Sentiment Indicator: Neutral. Pre-planned sales are common and do not typically affect market sentiment.
Additional Context
Special Circumstances
- The filing explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted by the insider on November 26, 2024. This automates transactions and is a defense against accusations of trading on inside information.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
